PrEParing to End the Epidemic
Optimizing HIV Prevention in Primary Care
Meeting Slides
Patient Poster
Clinical Practice Guidelines
Preexposure prophylaxis for the prevention of HIV infection in the United States—2021 update). A clinical practice guideline.
US Public Health Service. Centers for Disease Control and Prevention; 2021.
Sexually transmitted infections treatment guidelines. 2021.
Centers for Disease Control and Prevention. Last reviewed July 2021.
2018 quick reference guide: recommended laboratory HIV testing algorithm for serum or plasma specimens.
CDC Stacks. Centers for Disease Control and Prevention; last updated January 2018.
Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV—United States, 2016.
CDC Stacks. Centers for Disease Control and Prevention; last updated May 2018.
HIV pre-exposure prophylaxis in the EU/EEA and the UK: implementation, standards and monitoring: technical guidance.
European Centre for Disease Prevention and Control (ECDC). 2021.
The Fenway Guide to Lesbian, Gay, Bisexual, and Transgender Health.
Makadon H, et al, American College of Physicians (ACP), eds. 2nd ed. Boston, MA: Fenway Health; 2015.
Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society—USA Panel.
Saag MS, et al. JAMA. 2020;324(16):1651-1669.
Professional Organizations & Resources
American Academy of HIV Medicine.
Basic statistics.
Centers for Disease Control and Prevention; updated April 2022.
National Clinician Consultation Center.
University of California, San Francisco; 2020.
HIV drug interactions.
University of Liverpool (website); updated April 2022.
Suggested Readings
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten JM, et al. N Engl J Med. 2012;367(5):399-410.
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Choopanya K, et al. Lancet. 2013;381(9883):2083-2090.
Emtricitabine/tenofovir alafenamide.
HIV.gov. Drug database.
Emtricitabine/tenofovir disoproxil fumarate.
HIV.gov. Drug database.
Cabotegravir.
HIV.gov. Drug database.
Being PrEPared—preexposure prophylaxis and HIV disparities.
Goldstein RH, et al. N Engl J Med. 2018;379(14):1293-1295.
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant RM, et al. N Engl J Med. 2010;363(27):2587-2599.
Lifetime risk of a diagnosis of HIV infection in the United States.
Hess KL, et al. Ann Epidemiol. 2017;27(4):238-243.
Cabotegravir for HIV prevention in cisgender men and transgender women.
Landovitz RJ, et al. N Engl J Med. 2021;385(7):595-608.
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Mayer KH, et al. Lancet. 2020;396(10246):239-254.
Clinical Commissioning Policy. Reimbursement for the use of generic drugs for pre exposure prophylaxis (PrEP) for the prevention of HIV.
National Health Service. 2020.
How to incorporate HIV PrEP into your practice.
Stewart J, Stekler JD. J Fam Pract. 2019;68(5):254-261.
Patient and Provider assistance: PleasePrEPMe.org
Information about PrEP, nPEP, insurance and insurance rights, finding a PrEP/nPEP provider, and a list of PrEP resources by state
Provider assistance: AETC; AIDS Education & Training Center Program: National Coordinating Resource Center
Supports national HIV priorities by providing training, consultation, and resources
Ready, Set, PrEP! provides free PrEP HIV-prevention medication
Clinic visits and lab tests vary depending on income
If PrEP medication is a good option for your clients, they can choose the application process that is most convenient
By phone: 855-447-8410
Patient assistance (without insurance)
The PrEP patient assistance program will provide medication at no cost for those who meet income guidelines
Uninsured 24/7 support online, by phone during business hours and fax enrollment
Copay assistance (for patients with nongovernment insurance)
Phone number: 1-877-505-6986
Copay assistance/out-of-pocket costs
ViiV Connect
Relevant Resources
Improved Diagnostic and Management Strategies
Long-Term Management Strategies to Improve Patient Outcomes
Overcoming Pain and Gastrointestinal Distress to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Proactive Diagnosis and Targeted Management
Differential Diagnosis and Comprehensive Management Strategies
Optimizing Maintenance Therapy Across Healthcare Settings
Evolving Strategies for Diagnosis and Long-Term Management
Consensus and Controversies for Responsible Opioid Prescribing
Best Practices in Combination Therapy
Evolving Approaches to Insulin Based Therapy
Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms
Improving Outcomes for Patients with COPD
New Strategies for Insulin Replacement Therapy
Clinical Updates in LDL-C Management
Improving Comprehensive Patient Care
Identifying Patients and Tailoring Therapy
Collaborative Approaches to Guideline-Concordant Patient Care
New Strategies for Individualizing Long-term Care
A Focus on Patients With Opioid-Induced Constipation
Consensus and Controversies Across the Spectrum of Patient Presentations
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Pathophysiology to the Management of Moderate-to-Severe Disease
Evolving Best Practices to Optimize Outcomes
The PCPs Role in Preventing HIV
Targeting Immune Dysregulation and Delivering Comprehensive Care
The PCP’s Role in Timely Recognition and Referral
What Do You Know About PrEP?
Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care
What Do You Know About PrEP?
Translating Comprehensive Patient Evaluations Into Personalized Therapy
Got it? Treat it!
Looking Beyond Barriers to Optimize Therapy
New Perspectives on Targeting Remission and Individualizing Therapy
The Critical Role of the Community Pharmacist
Using Imaging to Improve Patient Outcomes
Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box
Discussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs
Differential Diagnosis, Multidisciplinary Management, and Patient Engagement
Key Issues Impacting OB/GYN Practice
Translating Pathophysiology into Targeted Treatments
Think You Know JAK?
An Interactive Experience Highlighting Recent Clinical Advances
Hot Topics in HBV, HCV, and NASH
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Debates & Discussions on the Evolving Role of JAK Inhibitors
Why It Matters in OB/GYN Practice Today
Improving Patient Outcomes Through Shared Clinical Decision Making
A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities
How the Pharmacist Can Make a Difference
Mechanistic Insights and Evolving Treatment Options
HIV Can Be Prevented— Are You Doing Your Part?
Rapid Start ART — A New Model for HIV Care
Clinical Resource Center
The Evolving Role of JAK Inhibitors
Understanding the Growing Syndemic — Opioids, HCV, and HIV
Unpacking the Evidence for Their Use Today and Tomorrow
A Case-Based Conversation on Managing Asthma and Chronic Rhinosinusitis With Nasal Polyposis
The Clinical and Utilization Benefits of Exacerbation Prevention
A PrEP Primer
A Foundation for Managed Care
Cardiovascular and Renal Outcomes With SGLT2 Inhibitors
Best Practices for Primary Care
New Paths to Chronic Pain Management
The PCP’s Role in HCV Elimination
What the Pharmacist Needs to Know about PrEP
The Rapid ART Standard of Care: From Evidence to Healthcare Equity
Unlocking Novel Paths to Patient Care
Maximizing Your Role to Impact Patient Outcomes
Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
Benefits, Barriers, & Best Practices in an Advancing Field
Practical Solutions Across the Spectrum of Care
Informing the Future of NASH Diagnosis and Assessment
A PEP/PrEP Training Guide for Pharmacists
The Increasing Role of JAK Inhibitors
Unlocking Novel Paths to Patient Care
New Pathways to Patient Management
A Focus on Clinical Evidence and Guideline Recommendations
Preventing COPD Exacerbations to Improve Outcomes
A Critical Step Toward HCV Elimination
Considering the Patient, the Provider, and the Science
A Multidisciplinary Online Mini-Curriculum
A Whole Patient Case Series
Debates and Discussions about Monoclonal Antibody Therapies
An Update on Monoclonal Antibody Therapies
New Avenues to the Management of Severe Asthma
Getting on the Fast Track to Identify AxSpA
Establishing Clinical Readiness Through Mentored Learning
Interdisciplinary Strategies for Adult and Pediatric Patients
Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema
Reducing LDL-C and a Lifetime of Cardiovascular Risk
Updates, Clinical Scenarios, and Future Directions
A Multidisciplinary Look at Early Diagnosis and Management
Finding the Path in Chronic Rhinosinusitis with Nasal Polyps
Recent Developments in Anti-SARS-CoV-2 Monoclonal Antibodies for Treatment
Best Practices for Diagnosis and Management
An Update on Best Practices
New Avenues to Pre-Exposure Prophylaxis
Are You Aware of New Blood-Based Multi-Cancer Screening Tools
From Patient Evaluations to New Targeted Therapies
An Updated Clinician’s Guide to Assessment and Management
What the Pharmacist Needs to Know
A Look at the Changing HIV Playing Field
A “How To” Series Spanning Policy to Practice
Test Your Mastery!
Building Bridges to Reach People who Inject Drugs with the Goal of Employing PrEP for HIV Prevention
Strengthening Your Knowledge of Blood-Based Screening Tools
Bringing HIV Prevention to a New Level
What You Need to Know About New Blood-Based Screening Tools
Monoclonal Antibodies for the Prevention and Treatment of COVID-19
New Avenues to Improve Patient Outcomes
Exploring New Treatment Avenues in Nonadvanced Systemic Mastocytosis
Practical Updates on the 2023 GOLD Guidelines
A Phone-a-Friend CME Series – Volume 2
Best Practices for Screening, Diagnosis, and Management
Incorporating New Data and Updated Guidelines Into Daily Practice
Focus on Psoriasis
Capitalizing on BCMA-Directed Therapies
